All Stories

  1. The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
  2. The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: a systematic review
  3. Prostanoid receptors in GtoPdb v.2025.3
  4. Endothelium-derived C-type natriuretic peptide offsets the pathogenesis of pulmonary hypertension
  5. MicroRNA regulation of PPARG Signalling: Therapeutic implications for pulmonary hypertension
  6. Circulating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis
  7. Functional Genomics Validation of PPAR gamma Signalling in PASMCs: Therapeutic Implications for Pulmonary Arterial Hypertension
  8. Thomas (Tom) B. Bolton – a major force in smooth muscle research
  9. 75 CIRCULATING EXTRACELLULAR VESICLES AS DIAGNOSTIC BIOMARKERS FOR INDETERMINATE THYROID NODULES
  10. Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats
  11. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  12. Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension
  13. Prostanoid receptors in GtoPdb v.2023.1
  14. OGC P05 Liquid biopsy in oesophageal cancer: a systematic review of blood biomarkers for early diagnosis
  15. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature
  16. SPOD2 Microvesicles as biomarkers for the screening of colorectal neoplasm
  17. The role of microvesicles as biomarkers in the screening of colorectal neoplasm
  18. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  19. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
  20. Prostanoid receptors in GtoPdb v.2021.2
  21. Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  22. International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions
  23. Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients
  24. Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension
  25. Synthetic routes to treprostinil N-acyl methylsulfonamide
  26. Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity
  27. Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  28. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  29. Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension
  30. Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  31. Exploring the enzymatic degradation of poly(glycerol adipate)
  32. Selexipag in the management of pulmonary arterial hypertension: an update
  33. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension
  34. Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
  35. RALINEPAG REDUCES PULMONARY VASCULAR RESISTANCE (PVR) IN A PHASE 2 STUDY CONFIRMING PRECLINICAL FINDINGS ON PROSTACYCLIN (IP) RECEPTORS IN HUMAN TISSUES
  36. Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).
  37. Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
  38. Improving Interpretation of Cardiac Phenotypes and Enhancing Discovery With Expanded Knowledge in the Gene Ontology
  39. EP4 agonists have reduced bronchodilation activity in patients with Group III pulmonary hypertension
  40. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  41. The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery
  42. 5021APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery
  43. Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart
  44. Inotropic Effects of Prostacyclins on the Right Ventricle Are Abolished in Isolated Rat Hearts With Right-Ventricular Hypertrophy and Failure
  45. Abstracts from the 10th World Congress for Microcirculation
  46. Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries
  47. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents
  48. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors
  49. Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension
  50. Counteracting effects of treprostinil and endothelin (ET-1) receptor antagonists (ETRAs) on endothelin-1, ETB receptor and ECE-1 levels in pulmonary smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension (PAH)
  51. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor
  52. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins
  53. Attenuated vascular responsiveness to K+ channel openers in diabetes mellitus: the differential role of reactive oxygen species
  54. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist
  55. Inhibition of vascular adenosine triphosphate-sensitive potassium channels by sympathetic tone during sepsis
  56. BK Large Conductance Ca2+-Activated K+ Channel-Deficient Mice are not Resistant to Hypotension and Display Reduced Survival Benefit Following Polymicrobial Sepsis
  57. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors
  58. Retraction Note: The large-conductance Ca2+-activated K+ channel is essential for innate immunity
  59. Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension
  60. Ca2+/calcineurin regulation of cloned vascular KATP channels: crosstalk with the protein kinase A pathway
  61. VARIABLE EFFECTS OF INHIBITING iNOS AND CLOSING THE VASCULAR ATP-SENSITIVE POTASSIUM CHANNEL (VIA ITS PORE-FORMING AND SULFONYLUREA RECEPTOR SUBUNITS) IN ENDOTOXIC SHOCK
  62. Different calcium mobilisation pathways underlie the changes in vascular reactivity to norepinephrine and vasopressin in septic shock
  63. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis*
  64. IP receptor-dependent activation of PPARγ by stable prostacyclin analogues
  65. Stoking Up BK Ca Channels in Hemorrhagic Shock
  66. Nuclear translocation of calcineurin Aβ but not calcineurin Aα by platelet-derived growth factor in rat aortic smooth muscle
  67. Endothelium-derived hyperpolarization factor (EDHF) is up-regulated in a pig model of acute liver failure
  68. Vasopressin: Mechanisms of action on the vasculature in health and in septic shock
  69. Role of KATP channels in sepsis
  70. Functional Expression of Inward Rectifier Potassium Channels in Cultured Human Pulmonary Smooth Muscle Cells: Evidence for a Major Role of Kir2.4 Subunits
  71. Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism
  72. Opportunities to Replace the Use of Animals in Sepsis Research
  73. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide
  74. The pore‐forming subunit of the KATP channel is an important molecular target for LPS‐induced vascular hyporeactivity in vitro
  75. The large-conductance Ca2+-activated K+ channel is essential for innate immunity
  76. The BK Channel
  77. Do Anionic Phospholipids Serve as Cofactors or Second Messengers for the Regulation of Activity of Cloned ATP-Sensitive K + Channels?
  78. Different molecular sites of action for the KATP channel inhibitors, PNU‐99963 and PNU‐37883A
  79. NO contributes to EDHF-like responses in rat small arteries: a role for NO stores
  80. The molecular site of action of KATP channel inhibitors determines their ability to inhibit iNOS-mediated relaxation in rat aorta
  81. Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the α or β catalytic subunit
  82. Assembly Limits the Pharmacological Complexity of ATP-sensitive Potassium Channels
  83. Terlipressin for norepinephrine-resistant septic shock
  84. Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery
  85. The Molecular Composition of KATP Channels in Human Pulmonary Artery Smooth Muscle Cells and Their Modulation by Growth
  86. Temporal variation in endotoxin‐induced vascular hyporeactivity in a rat mesenteric artery organ culture model
  87. A mechanism for ATP-sensitive potassium channel diversity: Functional coassembly of two pore-forming subunits
  88. Calcium Modulation of Vascular Smooth Muscle ATP-Sensitive K + Channels
  89. Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta
  90. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost
  91. Potassium channels in the vasculature
  92. Abnormal Activation of K+Channels Underlies Relaxation to Bacterial Lipopolysaccharide in Rat Aorta
  93. Ca(2+)-activated Cl- currents in pulmonary arterial myocytes
  94. Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes
  95. Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes
  96. Ca(2+)-activated Cl- and K+ channels and their modulation by endothelin-1 in rat pulmonary arterial smooth muscle cells
  97. KATP channels: fact or artefact?: commentaries
  98. Properties of the ATP-sensitive K+ current activated by levcromakalim in isolated pulmonary arterial myocytes
  99. Augmentation by intracellular ATP of the delayed rectifier current independently of the glibenclamide-sensitive K-current in rabbit arterial myocytes
  100. Calcium Channels and Vasodilation
  101. ATP-sensitive K+ channels mediate vasodilation produced by lemakalim in rabbit pulmonary artery
  102. Role for diacylglycerol in mediating the actions of ACh on M-current in gastric smooth muscle cells
  103. ATP-sensitive K+ channels regulate resting potential of pulmonary arterial smooth muscle cells
  104. Both membrane stretch and fatty acids directly activate large conductance Ca2+‐activated K+ channels in vascular smooth muscle cells
  105. Outward currents in rabbit pulmonary artery cells dissociated with a new technique
  106. Modulation of calcium movements by nitroprusside in isolated vascular smooth muscle cells
  107. Dual regulation of M current in gastric smooth muscle cells: β-adrenergic-muscarinic antagonism
  108. Substance P, like acetylcholine, augments one type of Ca2+ current in isolated smooth muscle cells
  109. Regulation of one type of Ca 2+ current in smooth muscle cells by diacylglycerol and acetylcholine
  110. Neurotransmitter Regulation of Ionic Channels in Freshly Dissociated Smooth Muscle Cellsa
  111. Acetylcholine increases voltage-activated Ca2+ current in freshly dissociated smooth muscle cells.
  112. Endothelial‐dependent relaxant actions of carbachol and substance P in arterial smooth muscle
  113. The diverse effects of noradrenaline and other stimulants on 86Rb and 42K efflux in rabbit and guinea‐pig arterial muscle.